Lu AF28996
DrugCapsule administered orally per schedule specified in the arm description.
NCT Number: NCT07513441
The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.
Interested in participating?
Request Info35 year–85 year
All sexes
Interventional
Phase 1
Beijing TiantanHospital, CapitalMedical University, Beijing, Beijing Municipality, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined inclusion and exclusion criteria may apply.
Capsule administered orally per schedule specified in the arm description.
Time frame: Up to 60 days
Time frame: Days 1, 21 or 31, and 41
Time frame: Days 1, 21 or 31, and 41
Time frame: Days 1, 21 or 31, and 41
Contact information is provided by the study sponsor or research team.
H. Lundbeck A/S
Industry
Interventional, Open-label, Trial Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AF28996 in Chinese Men and Women With Parkinson's Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07005180
Basal Ganglia Diseases, Brain Diseases
Farmington Hills, Michigan, United States
View Trial DetailsNCT06455293
Basal Ganglia Diseases, Behavior
San Francisco, California, United States
View Trial DetailsNCT05400174
Autonomic Nervous System Diseases, Basal Ganglia Diseases
San Diego, California, United States
View Trial DetailsNCT06976268
Basal Ganglia Diseases, Brain Diseases
Birmingham, Alabama, United States
View Trial Details